(Q51589277)

7 April 2018

title

No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. (English)

1 reference

7 April 2018

author

Francis Jacob

1

1 reference

7 April 2018

Viola Heinzelmann-Schwarz

8

object named as

Viola Heinzelmann-Schwarz

1 reference

7 April 2018

author name string

Mara Meier

2

1 reference

7 April 2018

Rosmarie Caduff

3

1 reference

7 April 2018

Darlene Goldstein

4

1 reference

7 April 2018

Tatiana Pochechueva

5

1 reference

7 April 2018

Neville Hacker

6

1 reference

7 April 2018

Daniel Fink

7

1 reference

7 April 2018

language of work or name

English

0 references

publication date

21 March 2011

1 reference

7 April 2018

published in

Gynecologic Oncology

1 reference

7 April 2018

volume

121

1 reference

7 April 2018

issue

3

1 reference

7 April 2018

page(s)

487-491

1 reference

7 April 2018

Reactivity of a monoclonal antibody with human ovarian carcinoma

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.02.022

A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.02.022

7 January 2021

Triage of ovarian masses

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.02.022

Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.02.022

Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.02.022

Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.02.022

Proteogenomic studies in epithelial ovarian cancer: established knowledge and future needs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.02.022

Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.02.022

Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.02.022

Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.02.022

Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.02.022

Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.02.022

The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.02.022

Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.02.022

The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.02.022

Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.02.022

A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.02.022

Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.02.022

Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.02.022

10.1016/J.YGYNO.2011.02.022

7 January 2021

Identifiers

DOI

1 reference

7 April 2018

1 reference

7 April 2018